OncLive
LightNews LightNews
banner
onclive.bsky.social
OncLive
@onclive.bsky.social
930 followers 140 following 2.5K posts
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
Posts Replies Media Videos
onclive.bsky.social
Durvalumab Plus Concurrent Chemoradiotherapy Fails to Show PFS or OS Benefit in NSCLC #lcsm #oncology www.onclive.com/view/durvalu...
Durvalumab Plus Concurrent Chemoradiotherapy Fails to Show PFS or OS Benefit in NSCLC | OncLive
Durvalumab administered with chemoradiotherapy rather than afterwards generated no significant improvement in PFS, OS, or ORR for patients with NSCLC.
www.onclive.com
November 28, 2025 at 1:12 PM
onclive.bsky.social
Mayo Clinic Researchers Identify Why Some Lung Tumors Respond Well to Immunotherapy @mayocliniccancer.bsky.social

www.onclive.com/view/mayo-cl...
Mayo Clinic Researchers Identify Why Some Lung Tumors Respond Well to Immunotherapy | OncLive
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
www.onclive.com
November 26, 2025 at 8:19 PM
onclive.bsky.social
Ziftomenib Added to NCCN Clinical Practice Guidelines for NPM1-Mutant R/R AML #leusm #hematology
www.onclive.com/view/ziftome...
Ziftomenib Added to NCCN Clinical Practice Guidelines for NPM1-Mutant R/R AML | OncLive
The NCCN guidelines for AML have been updated to include ziftomenib as a category 2A recommendation for NPM1-mutant, relapsed/refractory AML management.
www.onclive.com
November 26, 2025 at 5:25 PM
onclive.bsky.social
T-DM1 Displays a Lower Cardiotoxicity Risk vs Other HER2-Targeted Regimens in HER2+ Breast Cancer #oncology #bcsm
www.onclive.com/view/t-dm1-d...
T-DM1 Displays a Lower Cardiotoxicity Risk vs Other HER2-Targeted Regimens in HER2+ Breast Cancer | OncLive
T-DM1 showed the lowest LVEF decline vs other HER2-targeted regimens, underscoring key differences in cardiac safety.
www.onclive.com
November 26, 2025 at 3:19 PM
onclive.bsky.social
Cevostamab-Based Combos Could Represent Next Bispecific Antibody Approach in R/R #Myeloma

www.onclive.com/view/cevosta...
Cevostamab-Based Combos Could Represent Next Bispecific Antibody Approach in R/R Myeloma | OncLive
Joshua Richter, MD, discusses the evaluation of the FcRH5 x CD3 bispecific antibody in multiple myeloma.
www.onclive.com
November 25, 2025 at 5:49 PM
onclive.bsky.social
Subcutaneous Toripalimab Plus Chemo Meets PK End Points in Recurrent/Metastatic Nonsquamous #NSCLC

www.onclive.com/view/subcuta...
Subcutaneous Toripalimab Plus Chemo Meets PK End Points in Recurrent/Metastatic Nonsquamous NSCLC | OncLive
Subcutaneous toripalimab generated non-inferior efficacy and safety outcomes vs the IV formulation in recurrent/metastatic non squamous NSCLC.
www.onclive.com
November 25, 2025 at 3:46 PM
onclive.bsky.social
Sacituzumab Tirumotecan Plus Pembrolizumab Improves PFS in PD-L1+ Advanced NSCLC #lcsm #oncology www.onclive.com/view/sacituz...
Sacituzumab Tirumotecan Plus Pembrolizumab Improves PFS in PD-L1+ Advanced NSCLC | OncLive
Sacituzumab tirumotecan plus pembrolizumab improved PFS as first-line treatment in PD-L1–positive advanced NSCLC.
www.onclive.com
November 24, 2025 at 4:04 PM
onclive.bsky.social
Patient Factors Drive Chemotherapy Decision-Making in Metastatic #PancreaticCancer @mdanderson.bsky.social #PancreaticCancerAwareness

www.onclive.com/view/patient...
Patient Factors Drive Chemotherapy Decision-Making in Metastatic Pancreatic Cancer | OncLive
Shubham Pant, MD, MBBS, explores frontline chemotherapy decision-making in metastatic pancreatic cancer.
www.onclive.com
November 24, 2025 at 3:42 PM
onclive.bsky.social
Vorasidenib Shows Rapid Real-World Uptake in IDH-Mutated Glioma @neuroonc.bsky.social #SNO2025 #oncology #glioma
www.onclive.com/view/vorasid...
Vorasidenib Shows Rapid Real-World Uptake in IDH-Mutated Glioma | OncLive
Vorasidenib is being integrated in the real-world setting for the treatment of patients with IDH-mutated glioma.
www.onclive.com
November 24, 2025 at 1:11 PM
onclive.bsky.social
8F-Fluciclovine Imaging Differentiates Progression From Treatment-Related Changes in Brain Metastases @uwsph.bsky.social @neuroonc.bsky.social #SNO25 #oncology www.onclive.com/view/18f-flu...
18F-Fluciclovine Imaging Differentiates Progression From Treatment-Related Changes in Brain Metastases | OncLive
18F-Fluciclovine PET/MRI detected disease progression and ruled out disease in non-progressors among patients with solid tumor brain metastases.
www.onclive.com
November 23, 2025 at 11:29 PM
onclive.bsky.social
Erdafitinib Is Safe and Shows Preliminary Efficacy in F3T3 Fusion+ Glioma @neuroonc.bsky.social #SNO25 #oncology www.onclive.com/view/erdafit...
Erdafitinib Is Safe and Shows Preliminary Efficacy in F3T3 Fusion+ Glioma | OncLive
Erdafitinib had a safety profile that was deemed tolerable in patients with recurrent or progressive IDH wild-type glioma harboring F3T3 gene fusions.
www.onclive.com
November 23, 2025 at 3:31 AM
onclive.bsky.social
Eflornithine Plus Lomustine Extends PFS, OS in Reclassified WHO Grade 3 IDH-Mutated Astrocytoma @huntsmancancer.bsky.social #SNO2025 #btsm #oncology www.onclive.com/view/eflorni...
Eflornithine Plus Lomustine Extends PFS, OS in Reclassified WHO Grade 3 IDH-Mutated Astrocytoma | OncLive
Eflornithine plus lomustine produced superior OS and PFS outcomes vs lomustine in WHO grade 3 IDH-mutated astrocytoma.
www.onclive.com
November 23, 2025 at 2:24 AM
onclive.bsky.social
Temozolomide Plus Radiotherapy Yields Survival Benefit in IDH-Mutant LGG @neuroonc.bsky.social #SNO2025 #oncology
www.onclive.com/view/temozol...
Temozolomide Plus Radiotherapy Yields Survival Benefit in IDH-Mutant LGG | OncLive
Temozolomide plus radiotherapy significantly improved OS vs radiotherapy alone in IDH-mutant low-grade gliomas without codeletions of 1q and 19q.
www.onclive.com
November 23, 2025 at 1:57 AM
onclive.bsky.social
Mirdametinib Shows Improved ORR Over Time in NF1-Associated Symptomatic Plexiform Neurofibroma #SNO2025 #oncology www.onclive.com/view/mirdame...
Mirdametinib Shows Improved ORR Over Time in NF1-Associated Symptomatic Plexiform Neurofibroma | OncLive
Long-term ReNeu results showed deeper, more durable responses to mirdametinib in NF1-PN with extended treatment in both adults and children.
www.onclive.com
November 22, 2025 at 9:15 PM
onclive.bsky.social
CAR T-Cell Therapy Shows Early Safety in Recurrent Brain/Leptomeningeal Mets From HER2+ Breast Cancer
@cityofhope.bsky.social @neuroonc.bsky.social #SNO25 #bcsm #oncology www.onclive.com/view/car-t-c...
CAR T-Cell Therapy Proves Safe in Recurrent Brain/Leptomeningeal Mets From HER2+ Breast Cancer | OncLive
HER2-directed CAR T-cell therapy was safe in patients with brain/leptomeningeal metastases from HER2-positive breast cancer.
www.onclive.com
November 22, 2025 at 8:47 PM
onclive.bsky.social
B7-H3–Directed CAR T-Cell Therapy Has Acceptable Safety Profile in Recurrent Glioblastoma @uncdeptmedicine.bsky.social @unclineberger.bsky.social #SNO25 #oncology www.onclive.com/view/b7-h3-d...
B7-H3–Directed CAR T-Cell Therapy Has Acceptable Safety Profile in Recurrent Glioblastoma | OncLive
B7-H3–directed CAR T-cell therapy given intraventricularly was well tolerated and showed early efficacy signals in patients with recurrent glioblastoma.
www.onclive.com
November 22, 2025 at 5:01 AM
onclive.bsky.social
Mirdametinib Generates Responses and Is Safe in Pediatric Low-Grade Glioma @stjude.bsky.social @neuroonc.bsky.social #SNO25 #oncology #glioma #braincancer www.onclive.com/view/mirdame...
Mirdametinib Generates Responses and Is Safe in Pediatric Low-Grade Glioma | OncLive
Mirdametinib had clinical activity and was deemed well tolerated in MEK inhibitor–naive pediatric patients with recurrent/progressive low-grade glioma.
www.onclive.com
November 22, 2025 at 2:34 AM
onclive.bsky.social
Regorafenib Plus Temozolomide and RT Shows Early Signs of Tolerability in MGMT-Methylated, IDH Wild-Type Glioblastoma #SNO2025 #btsm #oncology www.onclive.com/view/regoraf...
Regorafenib Plus Temozolomide and RT Shows Early Signs of Tolerability in MGMT-Methylated, IDH Wild-Type Glioblastoma | OncLive
The RP2D of regorafenib when given with temozolomide and radiotherapy in patients with MGMT-methylated, IDH wild-type glioblastoma was 120 mg.
www.onclive.com
November 22, 2025 at 2:04 AM
onclive.bsky.social
Vorasidenib Plus Temozolomide Demonstrates Safety in IDH1/2+ Glioma
@neuroonc.bsky.social #SNO2025 #oncology #braincancer #glioma
www.onclive.com/view/vorasid...
Vorasidenib Plus Temozolomide Demonstrates Safety in IDH1/2+ Glioma | OncLive
Vorasidenib plus temozolomide was safe in glioma harboring IDH1/2 mutations.
www.onclive.com
November 22, 2025 at 1:41 AM
onclive.bsky.social
🚨 BREAKING NEWS 🚨: @fda.gov Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

Here's what you should know about the decision: www.onclive.com/view/fda-app...

#oncology #fdanews
November 21, 2025 at 5:29 PM
onclive.bsky.social
FDA Accepts NDA for Zidesamtinib in ROS1+ Advanced NSCLC After a Prior TKI #oncology #lcsm #NSCLC
www.onclive.com/view/fda-acc...
FDA Accepts NDA for Zidesamtinib in ROS1+ Advanced NSCLC After a Prior TKI | OncLive
Will the FDA approve zidesamtinib for ROS1-positive advanced non–small cell lung cancer after a prior TKI?
www.onclive.com
November 21, 2025 at 4:51 PM
onclive.bsky.social
CELMoDs Aim to Build on Established IMiDs in Multiple Myeloma Management @mountsinainyc.bsky.social #mmsm #hematology
www.onclive.com/view/celmods...
CELMoDs Aim to Build on Established IMiDs in Multiple Myeloma Management | OncLive
Joshua Richter, MD, discusses the exploration of CELMoDs in the treatment of patients with multiple myeloma.
www.onclive.com
November 21, 2025 at 1:22 PM
onclive.bsky.social
The Essential But Often Complex Role of Numbers and Measurements in Oncology @cityofhope.bsky.social #oncology
www.onclive.com/view/the-ess...
The Essential But Often Complex Role of Numbers and Measurements in Oncology | OncLive
Maurie Markman, MD, discusses the evolving role of measurements in cancer care.
www.onclive.com
November 20, 2025 at 7:52 PM
onclive.bsky.social
FDA Clears Oncomine Dx Target Test as Companion Diagnostic for Sevabertinib in NSCLC #oncology #lcsm #NSCLC
www.onclive.com/view/fda-cle...
FDA Clears Oncomine Dx Target Test as Companion Diagnostic for Sevabertinib in NSCLC | OncLive
The FDA OKs the Oncomine Dx Target Test to identify patients with HER2 TKD–mutant NSCLC eligible for sevabertinib, enabling targeted treatment selection.
www.onclive.com
November 20, 2025 at 6:28 PM
onclive.bsky.social
Venetoclax-Enhanced RBAC Shows Promise in High-Risk Mantle Cell Lymphoma #oncology #MCL
www.onclive.com/view/venetoc...
Venetoclax-Enhanced RBAC Shows Promise in High-Risk Mantle Cell Lymphoma | OncLive
Carlo Visco, MD, discusses phase 2 FIL_V-RBAC results showing venetoclax plus RBAC achieved a meaningful PFS and manageable toxicity in high-risk MCL.
www.onclive.com
November 20, 2025 at 6:22 PM